Acura Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results

 

BALANCE SHEETS  

Convenience

translation

December 31,

December 31,

2016

2017

2017

N I S

U.S. dollars

 CURRENT ASSETS:

Cash and cash equivalents

15,705

71,382

20,589

Marketable securities

2,017

-

-

Short-term deposits

7,602

-

-

 Other receivables

815

3,923

1,131

26,139

75,305

21,720

 LONG‑TERM ASSETS:

 Marketable securities

2,050

-

-

 Property, plant and equipment

1,443

5,510

1,589

 Other long term assets

478

880

254

3,971

6,390

1,843

30,110

81,695

23,563

 CURRENT LIABILITIES:

 Trade payables

686

6,223

1,795

 Other payables

689

660

190

1,375

6,883

1,985

 LONG‑TERM LIABILITIES:

Liability in respect of government grants

-

10,300

2,971

 Warrants

3,043

8,177

2,358

 Severance pay liability, net

76

83

24

3,119

18,560

5,353

 SHAREHOLDERS' EQUITY :-

 Ordinary shares of NIS 0.0000001 par value:

Authorized: 391,000,000 shares as of December 31, 2017;

Issued and Outstanding: 261,419,599, 135,097,367, shares

as of December 31 2017 and December 31, 2016, respectively

*) -

*) -

*) -

 Share premium

113,041

179,669

51,823

Options

1,435

-

-

 Other comprehensive income

6

-

-

 Accumulated deficit

(88,866)

(123,417)

(35,598)

25,616

56,252

16,225

30,110

81,695

23,563

*)            Represents an amount lower than NIS 1.

                         

                                                                                                                                                             

STATEMENTS OF COMPREHENSIVE INCOME  

In thousands, except per share data

Convenience translation

 

Year ended

December 31,

Year ended

December 31,

2015

2016

2017

2017

N I S

U.S. dollars

Operating expenses:

Research and development, net of participations

7,906

 

7,794

 

18,777

5,416

Marketing, general and administrative

3,397

4,106

4,879

1,407

Total operating expenses

11,303

11,900

23,656

6,823

Operating loss

(11,303)

(11,900)

(23,656)

(6,823)

Financial income

1,128

3,019

18

5

Financial expense

(24)

(303)

(10,913)

(3,148)

Loss  

(10,199)

(9,184)

(34,551)

(9,966)

Other comprehensive income (loss):

Items to be reclassified to profit or loss in subsequent periods:

Gain (loss) from available-for-sale marketable securities

(5)

(6)

 

(6)

 

(2)

Total comprehensive loss

(10,204)

(9,190)

(34,557)

(9,968)

Basic and diluted loss per share

(0.10)

(0.07)

(0.17)

(0.05)

Weighted average number of shares outstanding used to compute basic and diluted loss per share

105,522,642

 

135,097,367

 

 

201,030,768

 

 

201,030,768

Contact Details:

Joshua Phillipson

+972-8-930-2529

j.phillipson@biondvax.com  

Cision

View original content:http://www.prnewswire.com/news-releases/biondvax-announces-fourth-quarter-and-full-year-2017-financial-results-and-update-300639251.html

Source : https://finance.yahoo.com/news/biondvax-announces-fourth-quarter-full-200500373.html

Thank you for visit my website
BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
Merck Announces Full-Year and Fourth-Quarter 2012 Financial Results
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2013 Results and Hold Webcast
Alexion Pharmaceuticals (ALXN) Q4 2017 Results - Earnings Call Transcript
Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
Johnson & Johnson's 2014 revenue rose and profits soared
Tiffany’s Meets Lowered Estimates, Maintains Previous Outlook
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results
Juniper Pharmaceuticals Reports Full-Year 2017 Financial and Operating Results
Alexion Pharmaceuticals (ALXN) Q3 2017 Results - Earnings Call Transcript